• 09May

    Dr. Ira Kirschenbaum has reached a specific point in his career because of self-reliance and because of collaboration. Dr. Ira Kirschenbaum had to spend some quality time with his patients, with his fellow peers, and with other people within the larger healthcare ecosystem to get to where he was today.

    It Starts With Desire and Passion

    Dr. Ira Kirschenbaum knew that he was interested in the healthcare field. He had an interest and a desire to get to a better place in life and to do that by taking care of others. Dr. Ira Kirschenbaum could have entered into the business sector or other sectors and pursued profits over care but instead, he chose people and service. It is from this specific point, this focus and passion, that Dr. Ira Kirschenbaum was able to travel down a road and get to a specific point in his destination.

    Dr. Ira Kirschenbaum looked at the larger picture, chose to hone in on a specific path and he has found success by overcoming obstacles.

    Collaboration is Key in Career Development

    He knew that he could have tried to do everything by himself but he realized that he needed to work with others to understand, learn, and become better. If he were to operate by himself he would only be able to tap into his own consciousness, he wouldn’t be able to be in a space with others that are on a similar journey, picking up their skills, knowledge, and wisdom as well.

    He knew that there would be a variety of tasks within the work environment that he would have to take care of and that he would need to strategize to do them well. He could have tried to do them by himself but he realized that this would take a significant portion of his time. Instead, he realized that reaching out to others who have already been there and done that would help him to save time and be effective.

    Connect with Dr. Ira here https://twitter.com/doctor_ik?lang=en

  • 22Apr

    Famed doctor and Sunday Housecall talk show host, Dr. David Samadi says genetic markers for the early detection of prostate cancer can determine aggressiveness of tumors. Studies have shown that a particular protein appears to be directly related to the malignancy of prostate cancer. Dr. Samadi says this is exciting because doctors could distinguish an aggressively growing prostate cancer from a low-risk one, and this could indicate which therapy is best.

    Scientists from the International Cancer Genome Consortium searched databases containing molecular information on numerous prostate cancer cases. This data was used to test whether the tumor cells of any of the known control proteins are significantly more or less pronounced than healthy cells of the same patients. The researchers identified the most striking difference for the protein BAZ2A. Scientists say that this protein is known to impair the viability of cells. When the scientists switched off BAZ2A in metastatic prostate cancer cells, their growth slowed down.

    Studies also revealed that increased levels of BAZ2A boosts the malignant character of prostate cancer cells.

    Systematic studies of deceased men shows that about 30 percent of those in their fifties have latent prostate cancer. Only in a relatively small number of men, the tumor grows aggressive, forms metastases and must be treated.

    Dr. David Samadi says the PSA test is recommended and widely used around the world, that is, the measurement of the concentration of  prostate- specific antigen  in the blood, but the test have remained controversial. But these genetic markers, say Dr. Samadi, could determine malignancy early. If the results can be clinically confirmed, one would finally have the much sought-after marker to distinguish an aggressively growing prostate cancer from a low-risk one.

    Currently, doctor’s heavily rely on PSA testing, but it’s not foolproof. With these tests, indication of a possible cancer is arbitrary. It may well be that a person with a PSA level of 15 ml does not have carcinoma, but one with a value of 3 ml does. In half of the prostate tumors, and even in one third of invasive growing tumors, the PSA concentration is not increased. However, an increase in PSA over a longer period of time is a warning sign and must be closely monitored.

    A board-certified urologist, Dr. David Samadi has been treating urological diseases for over two decades. He attended Stony Brook University, earning his bachelor’s and medical degree, and then performed his residency at Montifiore Hospital, in the Bronx, New York. Dr. Samadi also was a fellow in oncology at Memorial Sloan Kettering Cancer Center.

    He’s been honored with more than 30 awards, that range from everything like Top Doctor, Patient’s Choice, and New York Metro’s Top Doctor, to being honored with the Community Partner Award, from the American Cancer Society, and two Castle Connolly Awards. Dr. Samadi is recognized for his expertise and achievements, all of the world, as well as being a sought-after surgeon, due to his specialty in minimally invasive surgery.

    Dr. David Samadi’s Social Media: www.youtube.com/user/RoboticOncology



Single Links